Long-term hepatitis E viral load kinetics in an immunocompromised patient treated with ribavirin.
Hepatitis E virus (HEV) can cause chronic infections in immunocompromised hosts. Viral kinetics in plasma and stools are poorly understood, particularly during antiviral treatment. Prolonged faecal shedding may be a concern for transmission. We describe HEV kinetics in an immunocompromised patient with prolonged faecal shedding despite undetectable viraemia on ribavirin treatment.
Virology Laboratory, Infectious Diseases Service, University Hospitals of Geneva, Geneva, Switzerland.
J
J
Ambrosioni
A
A
Mamin
A
A
Hadengue
M
M
Bernimoulin
K
K
Samii
C
C
Landelle
F
F
Negro
L
L
Kaiser
D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D003967:Diarrhea / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D004359:Drug Therapy, Combination; D005243:Feces / Q000821:virology*; D005260:Female; D016751:Hepatitis E / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D016752:Hepatitis E virus / Q000187:drug effects / Q000235:genetics; D006801:Humans; D016867:Immunocompromised Host; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome; D019562:Viral Load
D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000074323:Alemtuzumab; D012254:Ribavirin
Chronic infection; faecal shedding; hepatitis E virus; isolation; viral load